Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Florilglutamic acid F-18 is a radiopharmaceutical used as a tumor-specific positron emission tomography (PET) tracer. It is a radioactive L-glutamate derivative labeled with the radionuclide fluorine F 18. Upon intravenous administration, it targets and binds to the cystine/glutamate transporter protein (xCT or SLC7A11), which is part of the system xc(-). This transporter mediates cellular uptake of cystine in exchange for intracellular glutamate and is overexpressed in many tumor cells compared to normal tissue. The increased activity of this transporter in tumors allows for selective uptake and imaging by PET, enabling detection and assessment of tumor metabolism, proliferation, progression, chemoresistance, and oxidative stress management. Florilglutamic acid F-18 has been granted orphan designation for hepatocellular carcinoma diagnosis and has been investigated in clinical trials for imaging intracranial cancers and early lung cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Florilglutamic acid F-18.